PUBLISHER: Allied Market Research | PRODUCT CODE: 1193317
PUBLISHER: Allied Market Research | PRODUCT CODE: 1193317
The global pigmentation disorder treatment market was valued at $799.79 million in 2021, and is estimated to reach $1,220.91 million by 2031, growing at a CAGR of 4.3% from 2022 to 2031.
Pigmentation disorder is abnormality in the skin tissues, which can be diagnosed, evaluated, and treated in primary care practices. Skin color is caused by the melanin pigment. Melanocytes, a type of skin cell, produces it. Disorders of skin pigmentation can be brought on by a variety of medical conditions. Melasma, dark skin, and vitiligo are a few particular disorders that can result in skin discoloration. Vitiligo, pityriasis alba, tinea versicolor, and post inflammatory hypopigmentation are all conditions of hypopigmentation.
One of the major factors that drives the growth of the pigmentation disorder treatment market is increase in prevalence of pigmentation disorders. For instance, according to IP Indian Journal of Clinical and Experimental Dermatology published in January 2022, India is considered to have highest prevalence of vitiligo about 8.8%. In addition, increase in healthcare spending, rise in number of clinical research and product approvals contribute toward the global market growth. For instance, in July 2022 Incyte Corporation got approval from U.S. Food and Drug Administration (FDA) for its Opzelura (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
Furthermore, increase in the effort for pigmentation healthcare and rise in awareness about health problems are expected to drive the market growth. However high cost associated with the treatment is expected to hinder the market growth. Conversely, increase in healthcare expenditure is another factor expected to create lucrative opportunities for market growth during the forecast period
The pigmentation disorder treatment market is segmented on the basis of type, treatment, distribution channel, and region. On the basis of type, the market is categorized into vitiligo, melasma and others. The vitiligo segment is further classified as segmental and non-segmental. By treatment, it is divided into corticosteroids, calcineurin Inhibitor, and others. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies and online pharmacies. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
The major players profiled in the report are Arcutis Biotherapeutics, Inc, Astellas Pharma Inc., Bausch Health Companies Inc, Dermavant Sciences Inc, Dr. Reddy,s Laboratories Ltd, Galderma S.A, Glenmark Pharmaceuticals Limited, Incyte Corporation, Obagi Cosmeceuticals LLC and Viatris Inc.
Key Benefits For Stakeholders
By Type
By Treatment
By Distribution Channel
By Region